Compare · HTFL vs RMD
HTFL vs RMD
Side-by-side comparison of Heartflow Inc. (HTFL) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HTFL and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 7.7x HTFL ($4.43B).
- RMD has been more active in the news (9 items in the past 4 weeks vs 2 for HTFL).
- RMD has more recent analyst coverage (25 ratings vs 9 for HTFL).
- Company
- Heartflow Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $4.43B
- $34.07B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 9
- Recent ratings
- 9
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest HTFL
- SEC Form 4 filed by Heartflow Inc.
- Chief Medical Officer Rogers Campbell exercised 13,179 shares at a strike of $7.94 and sold $987,052 worth of shares (19,682 units at $50.15) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 79,956 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,230,742 worth of Common Stock. (24,345 units at $50.55) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 155,183 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,751,611 worth of Common Stock. (34,975 units at $50.08) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 179,528 units (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $1,819,605 worth of shares (38,900 units at $46.78) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 321,914 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $332,212 worth of Common Stock. (6,640 units at $50.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 214,503 units (SEC Form 4)
- UBS resumed coverage on Heartflow with a new price target
- Chief Financial Officer Verghese Vikram sold $1,665,796 worth of Common Stock. (33,416 units at $49.85) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 221,143 units (SEC Form 4)
- Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
- Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target